new_0222_0702|AMAM|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0702|AMAM|1|Ambrx Biopharma Inc Total Current Assets (Quarterly) (USD)|Ambrx Biopharma Inc Cash and Short Term Investments (Quarterly) (USD)|Ambrx Biopharma Inc Inventories (Quarterly) (USD)|Ambrx Biopharma Inc Net PP&E (Quarterly) (USD)|Ambrx Biopharma Inc Goodwill and Intangibles (Quarterly) (USD)|Ambrx Biopharma Inc Total Liabilities (Quarterly) (USD)|Ambrx Biopharma Inc Total Current Liabilities (Quarterly) (USD)|Ambrx Biopharma Inc Total Long Term Liabilities (Quarterly) (USD)|Ambrx Biopharma Inc Total Deposits (Quarterly) (USD)|Ambrx Biopharma Inc Book Value (Quarterly) (USD)|Ambrx Biopharma Inc Retained Earnings (Quarterly) (USD)|Ambrx Biopharma Inc Treasury Stock (Quarterly) (USD)|Ambrx Biopharma Inc EV to Revenues|Ambrx Biopharma Inc EV to Earnings|Ambrx Biopharma Inc EV to Free Cash Flow|Ambrx Biopharma Inc EV to Assets (Quarterly)|Ambrx Biopharma Inc PS Ratio|Ambrx Biopharma Inc PE Ratio|Ambrx Biopharma Inc Price to Book Value|Ambrx Biopharma Inc PEG Ratio|Ambrx Biopharma Inc Debt to Equity Ratio|Ambrx Biopharma Inc Dividend Yield|Ambrx Biopharma Inc Shareholder Yield (TTM)|Ambrx Biopharma Inc Percent of Shares Outstanding Short|Ambrx Biopharma Inc Total Receivables (Quarterly) (USD)|Ambrx Biopharma Inc Total Payables (Quarterly) (USD)|Ambrx Biopharma Inc Total Capital Stock (Quarterly) (USD)|Ambrx Biopharma Inc Return on Invested Capital|Ambrx Biopharma Inc Quality Ratio Score|Ambrx Biopharma Inc Momentum Score|Ambrx Biopharma Inc Beta (1Y)|Ambrx Biopharma Inc Sustainable Growth Rate (TTM)|Ambrx Biopharma Inc Institutional Investor Ownership Percentage|Ambrx Biopharma Inc Average Diluted Shares Outstanding (Quarterly)|Ambrx Biopharma Inc Total Employees (Annual)|Ambrx Biopharma Inc EPS Diluted (Quarterly) (USD)|Ambrx Biopharma Inc Shares Outstanding|Ambrx Biopharma Inc Repurchase of Capital Stock (Quarterly) (USD)|Ambrx Biopharma Inc Ordinary Shares Number (Quarterly)|Ambrx Biopharma Inc Payout Ratio|Ambrx Biopharma Inc Quick Ratio (Quarterly)|Ambrx Biopharma Inc Normalized Diluted EPS (Quarterly) (USD)|Ambrx Biopharma Inc Stock Buybacks (Quarterly) (USD)|Ambrx Biopharma Inc Effective Tax Rate (TTM)|Ambrx Biopharma Inc Return on Equity|Ambrx Biopharma Inc Net Income (TTM) (USD)|Ambrx Biopharma Inc Revenue (TTM) (USD)|Ambrx Biopharma Inc Dividend Per Share (Quarterly) (USD)|Ambrx Biopharma Inc Revenue (Quarterly) (USD)|Ambrx Biopharma Inc Gross Profit (Quarterly) (USD)|Ambrx Biopharma Inc SG&A Expense (Quarterly) (USD)|Ambrx Biopharma Inc Pre-Tax Income (Quarterly) (USD)|Ambrx Biopharma Inc Net Income (Quarterly) (USD)|Ambrx Biopharma Inc Net Interest Income (Quarterly) (USD)|Ambrx Biopharma Inc Price (USD)|Ambrx Biopharma Inc Total Return Price (USD)|Ambrx Biopharma Inc Enterprise Value (USD)|Ambrx Biopharma Inc 30-Day Average Daily Volume|Ambrx Biopharma Inc 1 Year Price Returns (Daily)||
new_0222_0702|AMAM|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0702|AMAM|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly||
new_0222_0702|AMAM|5|181|181||181|181|181|181|181||181|181||1.44378698225||1.44378698225||1.44117647059||1.43827160494||181|1.44378698225||15.3571428571|181|181|181||||||||||8||181|181|181|||181||181|181||||||||1.44117647059|1.44117647059|1.44378698225|1.44285714286|||
new_0222_0702|AMAM|6|1|1||1|1|1|1|1||1|1||169||169||170||162||1|169||14|1|1|1||||||||||2||1|1|1|||1||1|1||||||||170|170|169|140|||
new_0222_0702|AMAM|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0702|AMAM|202012|93.077|90.462||3.491|36.829|273.455|13.26|260.195||-139.434|-145.553||||||||||||||0.982|2.82|||||||||||||263.6862||6.8962|||-0.0056||-16.543|13.671||||||||||||||
new_0222_0702|AMAM|202103|||||||||||||||||||||||||||||||||||70||||||||||||||||||||||||||
new_0222_0702|AMAM|202106|173.029|167.201||2.957|37.337|20.928|17.484|3.444||192.797|-174.563||42.0288|-12.9099|-12.5642|2.4233|31.9735||3.5536||||-17.047|0.0201|0.888|3.768|0.024|-150.3589||||-150.3589|||||34.9552||244.6864||9.6139|||-0.0024|-150.3589|-40.118|12.323||||||||19.6|19.6|517.9209|99249.5667||19.55|17.81
new_0222_0702|AMAM|202109|||||||||||||24.7257||-7.3915||22.0225||2.4476|||||0.0364|||||||||||||||||||||||||||||||13.5|13.5|304.6942|17101.2333||12.6|9.35
new_0222_0702|AMAM|202112|||||||||||||12.0461||-3.6011||14.7306||1.6372|||||0.0078|||||||||||||||||||||||||||||||9.03|9.03|148.4445|20198.9||4.84|4.15